ArticleIndian journal of endocrinology and metabolism
Clinical Utility of Next-Generation Sequencing-Based Molecular Panel in Thyroid Nodules.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The molecular testing of indeterminate thyroid nodules (ITNs) empowers clinicians to make informed treatment decisions. Despite being recommended by the ATA 2015 guidelines, the utility of molecular testing in India is hindered by challenges related to availability and cost-effectiveness, thereby limiting its widespread adoption. We aimed to evaluate the clinical utility of next-generation sequencing (NGS)-based molecular testing in Indian patients with ITNs. Methods: The study included patients with Bethesda III and IV and selected Bethesda II nodules who underwent Thyrotrack NGS-based assay on fine needle aspirate (FNA) material. Surgery was recommended for patients with clinically significant mutations, while others were followed sonographically. Post-surgical histopathology results were compared with mutation variants to calculate the sensitivity, specificity, and negative predictive value of the NGS assay. Results: Among 35 patients (mean age 37.7 ± 12.4 years, 80% female), 20 (57%) had clinically significant mutations. Surgery was performed on 11 patients. The most common mutation was RAS (detected in 15 patients), followed by BRAF, TSH-R, ETV6/NTRK3, and PAX8/PPARG. Post-surgical outcomes showed an overall sensitivity of 86% and a specificity of 74%, with a negative predictive value of 94%. Among the mutation-negative group, only one patient had a malignancy, and the rest were benign showing a high negative predictive value of the NGS-based testing. Conclusion: NGS-based assays provide a reliable and cost-effective option for ruling out malignancy in ITNs in India, offering a high negative predictive value and complementing ACR-TIRADS and Bethesda cytology classifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.